Almost half of all patents relating to the genes of marine organisms belong to one large international corporation, BASF, a new study reveals.  

In efforts to translate basic-science results into pharmaceuticals and other technologies, success cannot be taken for granted.

Small trials using younger donors and elderly recipients hint that mesenchymal stem cell transfers might reduce frailty. 

The editorial board at the International Journal of Occupational and Environmental Health accuses its publisher of promoting corporate interests.

Industry professionals make more than academic researchers, but for professors, it may not be about the money.

Graduate students from The Scripps Research Institute share how they prepared to enter policy, law, biotech, and beyond.

The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.

Heads of academia and industry mingled with the vice president and the secretary of Health and Human Services at a biotech summit.

The proposed changes follow revelations in recent years that committee members preparing reports for the Academies did not disclose industry relationships. 

A report finds that new medications still take about 12 years to go from patent to patient.